It's not over yet for troubled drug

Posted 10 July 2024 AM

There's still hope that Apellis' geographic atrophy (GA) treatment Syfovre could hit the Australian market despite a continuous back and forth to get the drug over the line in Europe.

It's nearing a year-and-a-half since the TGA accepted a Type C application, also known as a new indication application, for Syfovre in GA, a leading cause of blindness.

To see the whole article, please login